Patel Chirag K. 4/A

What Happened
Chirag K. Patel, President & Co‑CEO and a director of Amneal Pharmaceuticals (AMRX), received a grant of 544,663 performance-based restricted stock units (PSUs) on March 2, 2026. The award is reported at $0.00 (no cash paid); the filing classifies the transaction as a derivative award. The Form 4 is an amendment to the March 3, 2026 filing and corrects that 100% of the grant consists of performance‑based RSUs (not time‑based RSUs).

Key Details

• Transaction date: 2026-03-02; amended Form 4 filed 2026-03-27 (original Form 4 filed 2026-03-03).
• Grant: 544,663 performance-based restricted stock units (reported as the maximum number issuable).
• Price: $0.00 per unit (award/grant).
• Vesting mechanics: PSUs vest based on Amneal Class A share average closing price targets at the end of a three‑year performance period; payout may range from 0% to 200% of target. Any earned PSUs vest in full on Feb 28, 2029.
• Shares owned after transaction: not specified in the provided filing.
• Amendment note: This filing corrects the original Form 4 which inadvertently reported restricted stock units; the full grant is performance‑based RSUs.

Context
Performance-based RSUs are contingent awards — no shares or cash are received immediately and vesting depends on achievement of specified performance (stock price) criteria over the performance period. Such grants are common executive compensation and are different from open-market purchases or sales, so they do not directly signal an immediate insider buy or sell.